Although Nucb2/nesfatin-1 seems to play a role in the progression and invasiveness of breast [13], colon [19], prostate [23], renal [21], and endometrial cancer [14], there is also evidence that increased levels of Nucb2/nesfatin-1 trigger apoptosis in other malignancies, which as a result might render this unique peptide useful in the treatment of cancer. Here, NUCB2 is linked to endometrial cancer.